Clinical Trials Logo
  1. Home
  2. Ewing Sarcoma
  3. NCT06243588
  4. Details
NCT06243588 Clinical Trial

Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

Ewing Sarcoma Clinical Trial

Official title:
Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06243588
Other study ID # ProEwing
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 25, 2024
Est. completion date July 31, 2024

Study information
Verified date January 2024
Source Istituto Ortopedico Rizzoli
Contact Costantino Errani
Phone 0516366
Email costantino.errani@ior.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma. Identification of reliable prognostic factors could help to identify high-risk patients, which may require a different treatment and follow up.

Recruitment information / eligibility
Status Recruiting
Enrollment 400
Est. completion date July 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: - Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021 - Age = 2 years - Diagnosis of Ewing Sarcoma - Patients with available clinical and imaging data Exclusion Criteria: - At least one inclusion criterion not met

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• clinical records review
review the medical records, radiological imaging, and histological data of these patients

Locations
Country Name City State
Italy IRCCS Itituto Ortopedico Rizzoli Bologna BO

Sponsors (1)
Lead Sponsor Collaborator
Istituto Ortopedico Rizzoli

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Grunewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Alava E, Kovar H, Sorensen PH, Delattre O, Dirksen U. Ewing sarcoma. Nat Rev Dis Primers. 2018 Jul 5;4(1):5. doi: 10.1038/s41572-018-0003-x. — View Citation

Pressman BD, Tourje EJ, Thompson JR. An early CT sign of ischemic infarction: increased density in a cerebral artery. AJR Am J Roentgenol. 1987 Sep;149(3):583-6. doi: 10.2214/ajr.149.3.583. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Correlation Correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma. At baseline (Day 0)
See also
  Status Clinical Trial Phase
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting NCT06094101 - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Phase 1/Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Completed NCT00743496 - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma Phase 1
Recruiting NCT04337177 - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Phase 1
Active, not recruiting NCT02945800 - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Phase 2
Recruiting NCT06156410 - Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Phase 1
Recruiting NCT05968768 - To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) Phase 2
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT05093322 - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02856048 - Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Phase 2/Phase 3
Withdrawn NCT03880123 - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Phase 1
Completed NCT04956198 - Drug Sensitivity and Mutation Profiling
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Recruiting NCT06068075 - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD N/A
Active, not recruiting NCT03709680 - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Phase 1/Phase 2
Recruiting NCT05734066 - Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Phase 1/Phase 2
Completed NCT02044120 - ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma Phase 1